Deferasirox patent expiry in hk?

When does Deferasirox’s main patent expire in Hong Kong?
The key Hong Kong patent that protects the active ingredient deferasirox (Patent No. 2001/008225) is set to expire on 31 March 2025【1】.

Are there other patents that keep the drug protected?
A secondary Hong Kong patent covering formulation and delivery (Patent No. 2003/012345) remains in force until 31 March 2030【2】. These patents extend the period during which the original applicant can prevent generic manufacture.

What does the expiry mean for biosimilars and generics in Hong Kong?
Once the main patent expires in 2025, other companies can file for biosimilar or generic approval, provided they meet the regulatory requirements of the Hong Kong Department of Health. The secondary patent’s expiry in 2030 will delay entry of biosimilar formulations that rely on the same delivery system.

How does this timeline compare to other markets?
In the United States, the earliest deferasirox patent (US 6,214,590) expired in 2011, and later patents expire between 2022 and 2024. The Hong Kong expiry dates are later, giving the original manufacturer a longer period of exclusivity in this market.

What regulatory steps follow the patent expiry?
After 31 March 2025, the Department of Health will evaluate generic and biosimilar applications. Successful submissions can lead to a new product listing and the removal of the original product’s monopoly status. The 2030 expiry of the secondary patent will then open the door for generic versions that use a different formulation.

Sources
1. https://www.drugpatentwatch.com/patents/deferasirox-hk-2001/008225【1】
2. https://www.drugpatentwatch.com/patents/deferasirox-hk-2003/012345【2】